Treatment
Table 2. Recommendations
Quality of
Evidence
Strength of
Recommendation
Confidence
in Estimates
For patients with IPF, the guideline committee recommends:
Clinicians NOT use imatinib.
⊕⊕⊕⊖
Strong Moderate
Clinicians NOT use warfarin
anticoagulation in patients who do not have
a known alternative indication for its use.
⊕⊕⊖⊖
Strong Low
Clinicians NOT use the combination
therapy of N-acetylcysteine, azathioprine,
and prednisone.
⊕⊕⊖⊖
Strong Low
Clinicians NOT use ambrisentan, a
selective ER-A endothelin receptor
antagonist, regardless of the presence or
absence of PH.
⊕⊕⊖⊖
Strong Low
For patients with IPF, the guideline committee suggests:
Clinicians use nintedanib.
⊕⊕⊕⊖
Conditional Moderate
Clinicians use pirfenidone.
⊕⊕⊕⊖
Conditional Moderate
Clinicians NOT use sildenafil, a
phosphodiesterase-5 inhibitor.
⊕⊕⊕⊖
Conditional Moderate
Clinicians NOT use bosentan or
macitentan, both dual ER-A and ER-B
endothelin receptor antagonists.
⊕⊕⊖⊖
Conditional Low
Clinicians NOT use N-acetylcysteine
monotherapy.
⊕⊕⊖⊖
Conditional Low
Clinicians use regular anti-acid treatment.
⊕⊖⊖⊖
Conditional Very Low
